Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Christoph M Ahlers"'
Autor:
Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background The phase I first-in-human study ENGAGE-1 evaluated the humanized IgG1 OX40 agonistic monoclonal antibody GSK3174998 alone (Part 1 (P1)) or in combination with pembrolizumab (Part 2 (P2)) in patients with advanced solid tumors.Methods GSK3
Externí odkaz:
https://doaj.org/article/cede222f65c649b89ade485245fc9ae7
Autor:
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Daniel C Cho, F Stephen Hodi, Jan H M Schellens, Jennifer K Litton, Sandrine Aspeslagh, Karen A Autio, Frans L Opdam, Meredith McKean, Neeta Somaiah, Stephane Champiat, Mehmet Altan, Anna Spreafico, Osama Rahma, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Herbert Struemper, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore, Emmett V Schmidt, Axel Hoos, Aurelien Marabelle, Jeffrey S Weber, John V Heymach
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e005301
BackgroundThe phase I first-in-human study ENGAGE-1 evaluated the humanized IgG1 OX40 agonistic monoclonal antibody GSK3174998 alone (Part 1 (P1)) or in combination with pembrolizumab (Part 2 (P2)) in patients with advanced solid tumors.MethodsGSK317
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0dbbca2e6c06fe0b93fd49e0465c00d1
https://doi.org/10.1136/jitc-2022-005301
https://doi.org/10.1136/jitc-2022-005301
Autor:
Kevin J. Harrington, Praveen K. Bommareddy, Mark R. Middleton, Joseph J. Sacco, Anna Olsson-Brown, Tze Y. Chan, Pablo Nenclares, Isla Leslie, Francesca Aroldi, Imran Saleem, Christoph M. Ahlers, Henry Castro, Robert S. Coffin
Publikováno v:
Cancer Research. 82:CT155-CT155
Introduction: RP2 is a novel, enhanced potency oncolytic HSV1 which expresses GM-CSF, an anti-CTLA-4 antibody-like molecule and the fusogenic gibbon ape leukemia virus membrane R- glycoprotein (GALV-GP R-). RP2 is in clinical development in a range o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::714d9016842d0304cf0ab11790fb2b75
https://doi.org/10.1158/1538-7445.am2022-ct155
https://doi.org/10.1158/1538-7445.am2022-ct155
Autor:
Beata Holkova, Hang Quach, Christoph M. Ahlers, Nicola Jackson, Brandon E. Kremer, Niels W.C.J. van de Donk, Katja Weisel, Maria Brouch, Suzanne Trudel, Ellie Im, Sofia Paul, Paul G. Richardson, Rocio Montes de Oca, Shinta Cheng, Paula Rodriguez Otero, Geraldine Ferron-Brady, Kevin W. Song, L Smith, Monique C. Minnema, Ajay K. Nooka, David Routledge, Ira Gupta, Natalie S. Callander, Nahi Hareth
Publikováno v:
Future oncology (London, England). 17(16)
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody–drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dfb0fb0035e9e73f03ada82e657fa24
https://pubmed.ncbi.nlm.nih.gov/33682447
https://pubmed.ncbi.nlm.nih.gov/33682447
Autor:
Monique C. Minnema, Ellie Im, Frank G. Basile, Brandon E. Kremer, L. Mary Smith, Paul G. Richardson, Katarina Uttervall, Kevin W. Song, Paula Rodriguez-Otero, Hang Quach, Ajay K. Nooka, Ira Gupta, Herbert Struemper, Christoph M. Ahlers, Anne Yeakey, Morrys Kaisermann, Beata Holkova, Nicola Jackson, Suzanne Trudel, Natalie S. Callander, Rocio Montes de Oca
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S156
Background Single-agent belamaf, a B-cell maturation antigen-targeting antibody-drug conjugate, induced durable responses with a manageable safety profile in patients with RRMM at 13 months of follow-up (DREAMM-2; NCT03525678). The unique multimodal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e131d04229957651cc24c7489cb673d5
https://doi.org/10.1016/s2152-2650(21)02339-9
https://doi.org/10.1016/s2152-2650(21)02339-9
Autor:
Anne Yeakey, Paul G. Richardson, Chris Shelton, David Routledge, Ajay K. Nooka, Hareth Nahi, Suzanne Trudel, Hang Quach, Brandon E. Kremer, Kevin W. Song, Rocio Montes de Oca, Elaine M. Paul, Josephine Khan, Paula Rodriguez-Otero, Beata Holkova, Sofia Paul, Maria Brouch, Geraldine Ferron-Brady, Ira Gupta, Ellie Im, L. Mary Smith, Christoph M. Ahlers
Publikováno v:
Blood. 136:1-2
Introduction: Single-agent belamaf (GSK2857916), a B-cell maturation antigen-targeting antibody-drug conjugate, induced deep and durable responses in patients with RRMM, with a manageable safety profile with 13 months of follow-up (DREAMM-2; NCT03525
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d352b1fa88aa0b6c669205c27b499d5
https://doi.org/10.1182/blood-2020-139182
https://doi.org/10.1182/blood-2020-139182
Autor:
Jennifer K. Litton, Christoph M. Ahlers, Shelby A. Gorman, F. Stephen Hodi, Vincent K. Lam, Meredith McKean, Stéphane Champiat, Todd M. Bauer, Elaine M. Paul, Osama E. Rahma, Emmett V. Schmidt, Jeffrey S. Weber, Helen Zhou, Frans L. Opdam, Michael Chisamore, Jan H.M. Schellens, John V. Heymach, Axel Hoos, Mehmet Altan, Sandrine Aspeslagh, Aurélien Marabelle, Neeta Somaiah, Maura Watmuff, Daniel C. Cho, Willeke Ros, Herbert Struemper, Aaron R. Hansen, Anna Spreafico, Sophie Postel-Vinay, Kaitlin M. Yablonski, Niranjan Yanamandra, Karen A. Autio
Publikováno v:
Cancer Research. 80:CT150-CT150
Background: OX40 is a costimulatory receptor transiently expressed on the surface of activated T cells and some innate immune cells (e.g. NK cells). OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in precl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bab29054704bc2266f9e81c68f38cc50
https://doi.org/10.1158/1538-7445.am2020-ct150
https://doi.org/10.1158/1538-7445.am2020-ct150
Autor:
Thelma Netherway, Rocio Montes de Oca, Joanna Opalinska, Chris Shelton, Swethajit Biswas, Beata Holkova, Marc S. Ballas, Geraldine Ferron-Brady, Elaine M. Paul, Ira Gupta, Paul G. Richardson, Christoph M. Ahlers, Sofia Paul, Anne Yeakey, Nicola Jackson, Katarina Luptakova
Publikováno v:
Journal of Clinical Oncology. 38:TPS8552-TPS8552
TPS8552 Background: Single-agent belantamab mafodotin (GSK2857916), a B-cell maturation antigen targeting immunoconjugate, induced deep and durable responses in patients with RRMM, with a manageable safety profile (DREAMM-2, NCT03525678, Lancet Oncol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3df96b06ae91a5f91be92c66b6b7401a
https://doi.org/10.1200/jco.2020.38.15_suppl.tps8552
https://doi.org/10.1200/jco.2020.38.15_suppl.tps8552
Autor:
Deirdre Jill Cohen, Justin Callaway, Jill M. Marinis, James F. Smothers, Shubham Pant, Chetan Rathi, Andre Acusta, John Bertin, Bert H. O'Neil, Christoph M. Ahlers, James Winnberg, Adeline Verticelli
Publikováno v:
Journal of Clinical Oncology. 37:TPS4165-TPS4165
TPS4165 Background: The immunosuppressive myeloid infiltrate characteristic of the tumor microenvironment in pancreatic cancer represents a major therapeutic barrier in this disease. Modulation of this infiltrate may increase sensitivity to immune ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93360b22a96e697c006aa1c968ef29a2
https://doi.org/10.1200/jco.2019.37.15_suppl.tps4165
https://doi.org/10.1200/jco.2019.37.15_suppl.tps4165
Autor:
Akinobu Hamada, Suneet Shukla, Suresh V. Ambudkar, Sandra B. Ockers, Seth M. Steinberg, Douglas K. Price, Christoph M. Ahlers, Erin R. Gardner, William L. Dahut, Robert W. Robey, Tristan M. Sissung, William D. Figg
Publikováno v:
BJU International. 102:1694-1699
OBJECTIVE To determine if the C421A single nucleotide polymorphism (SNP) in the ATP-binding cassette transporter ABCG2 increases prostate cancer risk or affects survival. PATIENTS, SUBJECTS AND METHODS Numerous studies have suggested that dietary, ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ce4a19de814e4d7589b9b0c0521ac15
https://doi.org/10.1111/j.1464-410x.2008.07913.x
https://doi.org/10.1111/j.1464-410x.2008.07913.x